Fertility Preservation with Treatment of Immature Teratoma of the Ovary

Chia-Hui Chen1,2, Ming-Jie Yang1,2, Ming-Huei Cheng1,2, Ming-Shyen Yen1,2, Chiung-Ru Lai2,3, Peng-Hui Wang1,2*

Departments of 1Obstetrics and Gynecology and 3Pathology, Taipei Veterans General Hospital, and 2National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.

Fertility preservation for a patient with advanced immature teratoma of the ovary is reported. The patient, a 29-year-old woman, delivered a healthy baby after having had ovarian immature teratoma, grade 3, uncertain stage, at 13 years of age. She was initially treated with unilateral salpingo-oophorectomy and a contralateral wedge resection for tumor invasion, followed by a 6-course cisplatin + vinblastine + bleomycin regimen, a second operation, and an additional 6-course etoposide and cisplatin regimen with complete remission. The patient delivered a healthy baby 16 years after the initial treatment. Based on this successful case, intensive fertility-preserving surgery followed by chemotherapy, even in advanced-stage immature teratomas of the ovary, may be effective in preserving the reproductive function of women with malignant immature teratomas of the ovary. [J Chin Med Assoc 2007;70(5):218–221]

Key Words: fertility-preserving surgery, immature teratoma, ovary

Introduction

Pure immature teratoma is the second most common germ cell malignancy of all ovarian cancers; it represents <1%.1–4 However, in women younger than 20 years, it amounts to 10–20% of all ovarian malignancies, and contributes 30% of the ovarian cancer mortalities in this age group.5 About 50% of pure immature teratomas of the ovary occur in women between the ages of 10 and 20 years; hence, treatment to preserve their future fertility should be considered because the majority of ovarian germ cell tumors (OGCT) are curable with the aid of conservative surgery and follow-up combination chemotherapy.6,7 The first report of a successful pregnancy following conservative surgery and chemotherapy for advanced-stage immature teratoma appeared in 1989.8 With further advanced development of chemotherapy and more understanding of the disease course of ovarian immature teratoma, fertility-preserving surgery followed by multiagent chemotherapy has become a choice in patients with immature teratoma of the ovary. The following case report describes a woman with advanced immature teratoma of the ovary that had been treated with intensive conservative surgery and multiagent chemotherapy, who subsequently successfully delivered a baby.

Case Report

A 29-year-old woman, who had been diagnosed with and treated for ovarian tumor at 13 years of age, delivered a healthy baby. The initial treatment was unilateral salpingo-oophorectomy and wedge resection of the contralateral ovary. The final pathology showed ovarian immature teratoma, grade 3. The patient then received 6-course multiagent chemotherapy, including 3-day cisplatin 20 mg/m² + vinblastine 1.5 mg/m² + bleomycin 10 mg/m² (PVB), because of the presence of the immature teratoma, grade 3, uncertain stage (suspicious initial stage of at least International Federation of Gynecology and Obstetrics [FIGO] stage 1c) and incomplete staging surgery. Laparotomy was performed after the initial 6-course chemotherapy

*Correspondence to: Dr Peng-Hui Wang, Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C. E-mail: phwang@vghtpe.gov.tw  •  Received: September 19, 2006  •  Accepted: March 26, 2007
because imaging study showed residual tumors within the cul-de-sac and abdominal cavity. Tumor excision and complete staging surgery with fertility-preservation were performed. Pathology showed the residual tumor within the cul-de-sac to be an immature teratoma, grade 1, while the others, such as multiple sites of the random biopsies, were negative. Then, additional 6-course chemotherapy with a 3-day etoposide 100 mg/m² and cisplatin 20 mg/m² (EP) regimen was prescribed.

Menstruation occurred 1 year after complete therapy (at the age of 15 years). No menstruation disorder was recorded during the follow-up. The patient married at the age of 26 and underwent 3 cycles of clomiphene for ovarian induction due to 2-year subfertility but in vain. However, she became pregnant spontaneously without the assistance of a reproductive technique and delivered a healthy baby at the age of 29 years.

Discussion

Immature teratomas are solid tumors containing immature or embryonic tissues and account for approximately 20% of all malignant OGCT. Immature neuroepithelium is the predominant immature tissue found and can be used for tumor grading, such as grades 1, 2 and 3, when immature neuroepithelium occupies 0 or 1, ≤3, or ≥4 low-power fields (40×) per section, respectively. The prognosis of immature teratomas is governed by grade and stage. For example, cases of grade 1 in stage I might have up to a 94% survival rate, whereas cases of grade 2 or 3 in stage I might drop to an 82% chance of survival. Grade also contributes to the recurrence rate, with higher grades having a higher recurrence rate.

Treatment is dependent on the age of the patient and the specific tumor type. Although surgery is the most common form of treatment for immature teratoma, extensively destructive surgery, including total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, lymph node sampling and appendectomy is seldom considered for immature teratoma, except for those patients who have completed their fertility. Therefore, fertility-preserving surgery is the treatment of choice for younger women, because postoperative adjuvant chemotherapy has dramatically improved the prognosis of immature teratoma. In the present case, we further confirmed this concept.

Four controversial issues brought to our attention in this case should be mentioned: (1) the best combination chemotherapy regimen for malignant OGCT; (2) the role of second-look operation or secondary operation for malignant OGCT; (3) the consideration of ovarian function and future fertility in cancer patients; and (4) the safety of chemotherapy.

One of the great triumphs in the field of gynecologic oncology has been the attainment of cure in the vast majority of young patients with malignant OGCT. Smith and Rutledge had begun using the combination of vincristine, dactinomycin, and cyclophosphamide (VAC), with cure rates therefore unimaginable. The demise of the VAC regimen as standard therapy, however, was essentially sealed by the introduction of PVB and subsequent reports that revealed that VAC was very active for patients with stage I disease, but rather ineffective for those with advanced-stage tumors. Culine et al added etoposide to VPB and showed promising results in malignant OGCT; however, toxicity was very high. Because equal efficacy and less toxicity favored the combination of bleomycin, etoposide and cisplatin (BEP) as standard treatment for malignant OGCT in the 1990s, subsequent reports further confirmed the BEP regimen as first-line therapy for OGCT. To further decrease the toxicity of the BEP regimen, the following modifications were reported in the literature, including carboplatin used as a replacement for cisplatin in the BEP regimen and a 3-day modification protocol for the BEP regimen. Taken together, a postoperative 3-cycle or 4-cycle 3-day BEP (standard-dose cisplatin) regimen should be administered in patients with ovarian immature teratoma after fertility-preserving surgery.

Is there a place for second-look operation in OGCT? In our case, due to the initial incomplete surgery, the uncertain stage, teratoma component and of most importance, the visible “residual” tumor in the imaging study, all of which fulfilled the suggested criteria for second-look operation in OGCT in the literature, laparotomy might have been a better choice. The following conditions, including an incompletely resected tumor that contains a teratoma, or persistent radiologic abnormalities along with normal serum tumor markers at the end of chemotherapy, could lead to a consideration of second-look laparotomy or re-exploratory laparotomy.

Since patients with OGCT are young, what is the effect of chemotherapy on ovarian function or future fertility? A recent review addressed various views to expand possibilities for fertility preservation in cancer patients, including (1) the number of women who become infertile after cancer treatment is unknown; (2) infertility can affect patients with any cancer treated with radiation therapy or chemotherapy, but the greatest
risks are from chemotherapy involving alkylating agents
or whole-body irradiation;27 (3) surgeries that are common
for ovarian and cervical cancers can also compromise
fertility; and of most importance (4) none of the ferti-
ity preservation methods is clearly effective because all
of them tend to be expensive, unless there is a research
protocol that pays for medications or procedures.26 In
our case, the main therapies that would affect the
gonadotoxicity were destruction of the ovary, such as uni-
ilateral oophorectomy and partial oophorectomy of the
contralateral ovary or chemotherapy. Since a removed
ovary cannot be recovered, the preservation of future ferti-
ity should focus on the topic of chemotherapy, which may
induce gonadotoxicity. Chemotherapy-induced gonadotox-
icity is almost always irreversible.28 Histologic sections
of the ovary after treatment with cytotoxic drugs known to cause
ovarian failure show a spectrum of changes ranging from
decreased numbers of follicles to absent follicles to
fibrosis.29 The exact incidence of premature ovarian failure
after chemotherapy is difficult to establish because many factors contribute to ovarian failure. The
most important parameters are the age of the patient,
the drug class, and the cumulative dose of the drug.
The risk of gonadal damage increases as the age of the
woman increases and is most likely caused by the
presence of a lower number of remaining oocytes com-
pared with the younger patient. Cytotoxic chemother-
apeutic agents are not equally gonadotoxic,29 and the
toxic drugs are alkylating agents.28 These drugs may impair follicular maturation or deplete primordial
follicles. Temporary amenorrhea will result when matur-
ing follicles are destroyed by cytotoxic drugs, whereas
permanent amenorrhea or premature ovarian failure is
seen when all primordial follicles are destroyed.29

A recent review30 indicated that if chemotherapy is
administered to patients with OGCT, including imma-
ture teratoma, there is a risk of ovarian failure up to
approximately 30%.30–35 Other patients will sub-
sequently develop premature menopause. However, most
patients with OGCT may be treated with fertility-
sparing surgery followed by chemotherapy with preser-
vation of the fertility potential. Because the cure rates
approach 100% for those with early-stage disease and
are ≥75% for patients with advanced-stage disease, the
opportunity for future childbearing is excellent. The
outcomes of 5 large studies in terms of ovarian func-
tion and pregnancies following definitive treatment with
an incidence of normal menstruation ranged from
68% to 99%, and pregnancy numbers ranged from
19.7% to 72.5%.31–35 As noted, several successful preg-
nancies have been reported after primary surgery plus
combination chemotherapy,31–35 similar to our case.

Considering the safety of chemotherapy and since
lung toxicity can occur in chemotherapy containing
bleomycin, which shows cumulative toxicity, the
chemotherapy regimen followed by the secondary
operation in our case did not include bleomycin.

Taken together, irrespective of subtype and stage,
fertility-preserving surgery should be the first choice for
young patients with malignant OGCT if they have not
completed their family. Fertility seems to be only mar-
ginally affected by treatment. Miscarriages are in the
expected range for the general population. The malfor-
mation rate is slightly higher than in the general popu-
lation, but no significant difference was seen between
patients who did and did not receive chemotherapy.1

References
1. Lu KH, Gershenson DM. Update on the management of ovarian
perium: twelve-year experience at Veterans General Hospital –
3. Yuan CC, Ng HT, Chou MM, Chang MC, Liu HC. Malignant
germ cell tumors of ovary: a 15-year survey at VGH. J Chin
4. Wu RT, Torng PL, Chang DY, Chen CK, Chen RJ, Lin MC,
Huang SC. Mature cystic teratoma of the ovary: a clinicopatho-
5. Gershenson DM. Update on malignant ovarian cell tumors.
Cancer 1993;71:1581–90.
6. El-Lamie IK, Shehata NA, Abou-Loz SK, El-Lamie KJ. Conser-
tive surgical management of malignant ovarian germ cell
tumors: the experience of the Gynecologic Oncology Unit
7. Bakri YN, Ezzat A, Zahrani AD. Malignant germ cell tumors of
the ovary: pregnancy considerations. Eur J Obstet Gynecol
8. Lee RB, Kelly J, Elg SA, Benson WL. Pregnancy following conser-
tative surgery and adjunctive chemotherapy for stage III
9. O’Connor DM, Norris HJ. The influence of grade on the out-
come of stage I ovarian immature (malignant) teratomas and the
10. Norris HJ, Zirkin HJ, Benson WL. Immature (malignant) ter-
atoma of the ovary: a clinical and pathologic study of 58 cases.
11. Gershenson DM. The obsolescence of second-look laparotomy
in the management of malignant ovarian germ cell tumors.
Gynecol Oncol 1994;52:283–8.
12. Smith JP, Rutledge FN. Advances in chemotherapy for gynec-
13. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vini-
blastine, and bleomycin combination chemotherapy in dissem-
WT, Blessing JA. Vincristine, dactinomycin, and cyclophos-
phamide in the treatment of malignant germ cell tumors of the
ovary: a Gynecologic Oncology Group study (a final report).
Fertility-preserving surgery for ovarian immature teratoma


